ABL-602

N/A

Report date: 2026/03/19 17:18:31

Base Information

Drug NameABL-602

Drug Alias NameAnti-CLL-1 x CD3 bispecific antibodyCLL-1/CD3 bispecificABL-602

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionC-Type lectin domain family 12 member A modulatorsT cell surface glycoprotein CD3 modulators

TargetsC-Type lectin domain family 12 member AT cell surface glycoprotein CD3

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAbl Bio Inc

China Registration ClassN/A

Develop Information

Active CompaniesAbl Bio Inc

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A